Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

Springer Science and Business Media LLC - 2013
Isis B Yera-Alos1, Liuba Alonso-Carbonell1, Carmen Valenzuela-Silva2, Ángela D. Tuero-Iglesias2, Martha Moreira-Martínez3, Ivonne Marrero-Rodríguez4, Ernesto López-Mola2, Pedro López-Saura2
1Center for the Development of Pharmacoepidemiology, Havana, Cuba
2Center for Genetic Engineering and Biotechnology, Havana, Cuba
3“Abel Santamaría” Hospital, Pinar del Río, Cuba
4“Gustavo Aldereguía” Hospital, Cienfuegos, Cuba

Tóm tắt

Abstract Background After several exploratory and confirmatory clinical trials, the intralesional administration of human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of advanced diabetic foot ulcers (DFU). The aim of this work was to evaluate the effectiveness and safety of this procedure in medical practice. Methods A prospective, post-marketing active pharmacosurveillance was conducted in 41 hospitals and 19 primary care polyclinics. Patients with DFU received hrEGF, 25 or 75 μg, intralesionally 3 times per week until complete granulation of the ulcer or 8 weeks maximum, adjuvant to standard wound care. Outcomes measured were complete granulation, amputations, and adverse events (AE) during treatment; complete lesion re-epithelization and relapses in follow-up (median: 1.2; maximum 4.2 years). Results The study included 1788 patients with 1835 DFU (81% Wagner’s grades 3 or 4; 43% ischemic) treated from May 2007 to April 2010. Complete granulation was observed in 76% of the ulcers in 5 weeks (median). Ulcer non-ischemic etiology (OR: 3.6; 95% CI: 2.8-4.7) and age (1.02; 1.01-1.03, for each younger year) were the main variables with influence on this outcome. During treatment, 220 (12%) amputations (171 major) were required in 214 patients, mostly in ischemic or Wagner’s grade 3 to 5 ulcers. Re-epithelization was documented in 61% of the 1659 followed-up cases; 5% relapsed per year. AE (4171) were reported in 47% of the subjects. Mild or moderate local pain and burning sensation, shivering and chills, were 87% of the events. Serious events, not related to treatment, occurred in 1.7% of the patients. Conclusions The favorable benefit/risk balance, confirms the beneficial clinical profile of intralesional hrEGF in the treatment of DFUs.

Từ khóa


Tài liệu tham khảo

Armstrong DG, Cohen K, Courric S, Bharara M, Marston W: Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol. 2011, 5: 1591-1595.

Berlanga J: Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. Int Wound J. 2011, 8: 612-620. 10.1111/j.1742-481X.2011.00840.x.

López-Saura PA, Berlanga-Acosta J, Fernández-Montequín JI, Valenzuela-Silva C, González-Díaz O, Savigne W, Morejon-Vega L, Del Río-Martín A, Herrera-Martínez L, López-Mola E, Acevedo-Castro B: Intralesional human recombinant epidermal growth factor for the treatment of advanced diabetic foot ulcer: from proof of concept to confirmation of the efficacy and safety of the procedure. Global perspective on diabetic foot ulcerations. Edited by: Dihn T. 2011, Rijeka: InTech Europe, 217-238.http://www.intechopen.com/articles/show/title/intralesional-human-recombinant-epidermal-growth-factor-for-the-treatment-of-advanced-diabetic-foot-,

Berlanga J, Savigne W, Valdez C, Franco N, Alba JS, Del Rio A, López-Saura P, Guillén G, Lopez E, Herrera L, Férnandez-Montequín J: Epidermal growth factor intra-lesional can prevent amputation in diabetic patients with advanced foot wounds. Int Wound J. 2006, 3: 232-239. 10.1111/j.1742-481X.2006.00237.x.

Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA, Cuban Citoprot-P Study Group: Intralesional injections of Citoprot P® (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007, 4: 333-343.

Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, López Mola E, Galán-Naranjo K, Ramírez-Navas M, Bermúdez-Rojas S, Rosales F, García-Iglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Garcia-Siverio M, Herrera Martinez L: Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in advanced diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009, 6: 67-72. 10.1111/j.1742-481X.2008.00561.x.

Fernández-Montequín JI, Valenzuela-Silva CM, González-Díaz O, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Sánchez-Penton P, Morejón-Vega L, Artaza-Sanz H, García-Herrera A, González-Benavides C, Hernández-Cañete CM, Vázquez-Proenza A, Berlanga-Acosta J, López-Saura PA, for the Cuban Diabetic Foot Study Group: Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers. Multicenter, randomized, placebo-controlled, double blind study. Int Wound J. 2009, 6: 432-443. 10.1111/j.1742-481X.2009.00641.x.

Armstrong DG, Lavry LA, Harkless LB: Validation of a diabetic wound classification system: the contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998, 21: 855-859. 10.2337/diacare.21.5.855.

The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring: WHO Adverse reaction terminology 2008. 2008, Uppsala: UMC, Available from http://www.umc-products.com/DynPage.aspx?id=73589&mn1=1107&mn2=1664

Edwards RI, Biriell C: Harmonisation in pharmacovigilance. Drug Saf. 1994, 10: 93-102. 10.2165/00002018-199410020-00001.

National Report of the Population and Housing Census of Cuba 2002: 2002, La Habana: Bureau for Statistics, Available from: http://www.cubagob.cu/otras_info/censo/tablas_html/ii_3.htm; accessed on 06/23/2012

Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, Edmonds M, Holstein P, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, Van Acker K, Van Baal J, Van Merode F, Schaper N: High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007, 50: 18-25.

Fang RC, Galiano RD: A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics. 2008, 2: 1-12.

Chipchase SY, Treece KA, Pound N, Game FL, Jeffcoate WJ: Heel ulcers don’t heal in diabetes. Or do they?. Diabet Med. 2005, 22: 1258-1262. 10.1111/j.1464-5491.2005.01665.x.

Smith DI, Swamy PM, Heffernan MP: Off-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2). J Am Acad Dermatol. 2007, 56 (Suppl 1): e1-e54.

Graves JE, Nunle K, Heffernan MP: Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). J Am Acad Dermatol. 2007, 56 (Suppl 1): e55-e79.

Valenzuela-Silva CM, Tuero-Iglesias AD, García-Iglesias E, González-Díaz O, Del Río-Martín A, Year-Alos IB, Fernández-Montequín JI, López-Saura PA: Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant, human epidermal growth factor. Diabetes Care. 2013, 36: 210-215. 10.2337/dc12-1323.

Matricali GA, Deroo K, Dereymaeker G: Outcome and recurrence rate of diabetic foot ulcers treated by a total contact cast: short-term follow-up. Foot Ankle Int. 2003, 24: 680-684.

Frigg A, Pagenstert G, Schäfer D, Valderrabano V, Hintermann B: Recurrence and prevention of diabetic foot ulcers after total contact casting. Foot Ankle Int. 2007, 28: 64-69. 10.3113/FAI.2007.0012.

Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J: The global burden of diabetic foot disease. Lancet. 2005, 366: 1719-1724. 10.1016/S0140-6736(05)67698-2.

Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EYN, Kam G, Leung L, Chan CW, Chu CM, Lam EKH: Human epidermal growth. Factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003, 26: 1851-1856.

Viswanathan V, Pendsey S: A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D™ 150) in healing diabetic foot ulcers. Wounds. 2006, 18: 186-196.

Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor- B (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998, 21: 822-827. 10.2337/diacare.21.5.822.

Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T, Furue M: Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009, 19: 461-468.

Papanas N, Maltezos E, Benefit-Risk: Assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010, 33: 455-461. 10.2165/11534570-000000000-00000.

Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, Uccioli L, Urbancic V, Bakker K, Holstein P, Jirkovska A, Piaggesi A, Ragnarson-Tennvall G, Reike H, Spraul M, Van Acker K, Van Baal J, Van Merode F, Ferreira I, Huijberts M: Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008, 51: 747-755. 10.1007/s00125-008-0940-0.

Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV: Diabetic foot disorders: a clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006, 45 (Suppl 5): S1-S66.

Verdú J, Marinel-lo J, Armans E, Carreño P, March JR, Soldevilla J: National conference for consensus on low extremity ulcers. 2009, Spain: EdikaMed S.L, (in Spanish)

Snyder RJ, Kirsner RS, Warriner RA, Lavery LA, Hanft JR, Sheehan P: Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010, 56 (4 Suppl): S1-S24.

González-Acosta S, Calaña-González-Posada B, Marrero-Rodríguez I, López-Fernández R: Clinical evolution of diabetic foot treatment with Heberprot-P or with the conventional method. Rev Cubana Angiología y Cirugía Vascular. 2011, 11 (2): 11-(in Spanish). Available from http://bvs.sld.cu/revistas/ang/vol_11_2_11/ang07211.htm

García Herrera AL, Rodríguez Fernández R, Ruiz VM, Rodríguez Hernández L, Acosta Cabadilla L, Febles Sanabria R, Pancorbo Sandoval C, Cantero Calderón S, Vázquez Díaz O, Moliner Cartaya M: Reduction in the amputation rate with Heberprot P in the local treatment of diabetic foot. Spanish Journal of Surgical Research. 2011, XIV: 21-26. (in Spanish)

Lipsky BA: Medical treatment of diabetic foot infections. Clin Infect Dis. 2004, 39 (Suppl 2): S104-S114.

Iversen MM, Tell GS, Riise T, Hanestad BR, Østbye T, Graue M, Midthjell K: History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag health study, Norway. Diabetes Care. 2009, 32: 2193-2199. 10.2337/dc09-0651.

Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N: Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011, 171: 404-410. 10.1001/archinternmed.2011.2.

Ministry of Public Health: Cuban health yearbook 2011. 2012, La Habana, Available from: http://files.sld.cu/bvscuba/files/2012/05/anuario-2011-e.pdf

Brownrigg JRW, Davey J, Holt PJ, Davis WA, Thompson MM, Ray KK, Hinchliffe RJ: The association of ulceration of the foot with cardiovascular and all-cause mortality in patients with diabetes: a meta-analysis. Diabetologia. 2012, 55: 2906-2912. 10.1007/s00125-012-2673-3.

Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM: Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012, 35: 1835-1844. 10.2337/dc12-0002.

Berlanga-Acosta J, Gavilondo-Cowley J, García del Barco-Herrera D, Martín-Machado J, Guillen-Nieto G: Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinogene Mutagene. 2011, 2: 1-

Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana MD, López-Mola E, Guillén-Nieto G, Herrera-Martinez L: Epidermal Growth Factor (EGF) in clinical practice–a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009, 6: 331-346. 10.1111/j.1742-481X.2009.00622.x.

Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL: Postoperative mortality in cancer patients with preexisting diabetes. Diabetes Care. 2010, 33: 931-939. 10.2337/dc09-1721.

Hense HW, Kajüter H, Wellmann J, Batzler WU: Cancer incidence in type 2 diabetes patients -first results from a feasibility study of the D2C cohort. Diabetol Metabol Syndrome. 2011, 3: 15-10.1186/1758-5996-3-15.

Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, DeCamp MM: Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer. 2009, 115: 1059-1069. 10.1002/cncr.24133.

Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA: Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012, 23: 967-981. 10.1007/s10552-012-9972-3.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer. A consensus report. Diabetes Care. 2010, 33: 1674-1685. 10.2337/dc10-0666.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả